¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell surface receptor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • H1 receptor
    H1¼ö¿ëü
  • H2 receptor
    H2¼ö¿ëü
  • heat receptor
    ¿­¼ö¿ë±â
  • hairy skin receptor
    ÅÐÇǺμö¿ë±â
  • histamine receptor
    È÷½ºÅ¸¹Î¼ö¿ëü
  • homing receptor
    ±Í¼Ò¼ö¿ëü
  • immunoglobulin adhesion receptor
    ¸é¿ª±Û·ÎºÒ¸°ºÎÂø¼ö¿ëü
  • insulin receptor
    Àν¶¸°¼ö¿ëü
  • insulin receptor substrate-1
    Àν¶¸°¼ö¿ëü±âÁú-1
  • interferon receptor
    ÀÎÅÍÆä·Ð¼ö¿ëü
  • internalization receptor
    ³»ÀçÈ­¼ö¿ëü
  • joint receptor
    °üÀý¼ö¿ë±â
  • kinesthetic receptor
    ¿îµ¿°¨°¢¼ö¿ë±â
  • labyrinthine receptor
    ¹Ì·Î¼ö¿ë±â
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • scavenger cell
    û¼Ò¼¼Æ÷
  • Schwann's cell
    ½Å°æÁý¼¼Æ÷
  • signet ring cell carcinoma
    ¹ÝÁö¼¼Æ÷¾ÏÁ¾
  • signet-ring cell
    ¹ÝÁö¼¼Æ÷
  • small cell carcinoma
    ¼Ò¼¼Æ÷¾ÏÁ¾
  • spindle cell
    ¹æÃß¼¼Æ÷
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷»óÇdz»¾ÏÁ¾, ÆíÆò¼¼Æ÷¾ÏÁ¾
  • stellate cell
    º°¼¼Æ÷
  • stem cell
    Áٱ⼼Æ÷
  • supporting cell
    ¹öÆÀ¼¼Æ÷
  • sustentacular cell
    (¢¡supporting cell) ¹öÆÀ¼¼Æ÷
  • target cell
    Ç¥Àû¼¼Æ÷
  • transitional cell
    ÀÌÇ༼Æ÷
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • receptor autoradiography
    ¼ö¿ëüÀÚ°¡¹æ»ç¼±¼ú
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • cholinergic receptor
    Äݸ°¼ö¿ëü
  • cold receptor
    ³Ã°¢¼ö¿ëü
  • complement receptor
    µµ¿òü¼ö¿ëü, º¸Ã¼¼ö¿ëü
  • corpuscular receptor
    ¼Òü¼ö¿ëü
  • distance receptor
    (¢¡teleceptor) ¿ø°Ý¼ö¿ëü
  • dominant receptor
    ¿ì¼º¼ö¿ëü
  • early receptor potential
    Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • electromagnetic receptor
    ÀüÀÚ±â¼ö¿ëü
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • CR1 => complement receptor 1
    º¸Ã¼¼ö¿ëü 1
  • CR2 => complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • CR3 => complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • CR4 => complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • Gustatory receptor
    ¹Ì°¢¼ö¿ëü(Ú«ÊÆâ¥é»ô÷)
  • H2 receptor antagonist
    H2 ¼ö¿ëü ±æÇ×Á¦µé
  • Ig receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • Internalization, receptor
    ³»È­(Ò®ü§), ¼ö¿ëü(áôé»ô÷)
  • Kainate amino acid receptor
    Ä«À̳×ÀÌÆ® ¾Æ¹Ì³ë»ê ¼ö¿ëü(áôé»ô÷)
  • Kinesthetic receptor
    ¿îµ¿(ê¡ÔÑ)(°¨(Êï))°¢¼ö¿ëü(ÊÆáôé»ô÷)
  • NMDA receptor
    ¿£¾Úµð¿¡ÀÌ ¼ö¿ëü
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • acetylcholine receptor
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • mmuscle receptor
    ±Ù°¨¼ö±â
  • mu receptor
    ¹Â¼ö¿ëü
  • muscarinic receptor
    ¹«½ºÄ«¸° ¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±Ù¼ö¿ëü
  • nicotinic receptor
    ´ÏÄÚÆ¾ ¼ö¿ëü
  • olfactory receptor
    Èİ¢°¨¼ö±â
  • olfactory receptor cells
    Èİ¢¼ö¿ë¼¼Æ÷
  • opiate receptor
    ¾ÆÆí¼ö¿ëü(áôé»ô÷)
  • opiate receptor
    ¾ÆÆí¼ö¿ëü.
  • opioid receptor
    ¾ÆÆí¾ç¼ö¿ëü
  • opioid receptor
    ¾ÆÆí°è¹°Áú¼ö¿ëü.
  • opioid receptor
    ¾ÆÆí¾ç¹°Áú¼ö¿ëü.
  • opioid receptor
    ¾ÆÆí¾ç¹°Áú¼ö¿ëü.
  • paciniform receptor
    ÆÄÄ¡´Ï¾ç °¨¼ö±â
  • pathogen receptor
    º´¿ø±Õ¼ö¿ëü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Thyroid articular surface
    ¹æÆÐ°üÀý¸é
    [¿¾ ¿ë¾î] °©»ó°üÀý¸é
  • Ventral surface
    ¹èÂʸé
    [¿¾ ¿ë¾î] º¹Ãø¸é
  • Sternocostal surface
    º¹Àå°¥ºñ¸é
    [¿¾ ¿ë¾î] Èä´Á¸é
  • Gluteal surface
    º¼±â±Ù¸é
    [¿¾ ¿ë¾î] µÐ±Ù¸é
  • Buccal surface
    º¼¸é
    [¿¾ ¿ë¾î] Çù¸é
  • Mediastinal surface
    ¼¼·ÎÄ­¸é
    [¿¾ ¿ë¾î] Á¾°ÝºÎ
  • Internal surface
    ¼Ó¸é
    [¿¾ ¿ë¾î] ³»¸é
  • Dorsal surface of fingers
    ¼Õ°¡¶ôµî
    [¿¾ ¿ë¾î] ¼öÁö¹è¸é
  • Palmar surface of fingers
    ¼Õ°¡¶ô¹Ù´Ú
    [¿¾ ¿ë¾î] ¼öÁöÀå¸é
  • Carpal articular surface
    ¼Õ¸ñ°üÀý¸é
    [¿¾ ¿ë¾î] ¼ö±Ù°üÀý¸é
  • Inferolateral surface
    ¾Æ·¡°¡Âʸé
    [¿¾ ¿ë¾î] ÇÏ¿ÜÃø¸é
  • Inferior articular surface
    ¾Æ·¡°üÀý¸é
    [¿¾ ¿ë¾î] ÇϰüÀý¸é
  • Inferior surface
    ¾Æ·¡¸é
    [¿¾ ¿ë¾î] Çϸé
  • Vestibular surface
    ¾È¶ã¸é
    [¿¾ ¿ë¾î] ÀüÁ¤¸é
  • Medial surface
    ¾ÈÂʸé
    [¿¾ ¿ë¾î] ³»Ãø¸é
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
  • cell envelope
    ¼¼Æ÷(á¬øà)½Î°³
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • cell fractionation
    ¼¼Æ÷ºÐȹȭ(á¬øàÝÂüñûù)
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
  • cell-free extract
    ¹«¼¼Æ÷ÃßÃâ¹°(Ùíá¬øàõÎõóÚª)
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
  • cell hybridization
    ¼¼Æ÷(á¬øà) Æ¢±âÇü¼º(û¡à÷)
  • cell line
    ¼¼Æ÷ÁÖ(á¬øàñ»)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • red blood cell
    ÀûÇ÷±¸
  • reticulum cell
    ¼¼¸Á¼¼Æ÷
  • reticulum cell sarcoma
    ¼¼¸Á¼¼Æ÷À°Á¾
  • round cell
    ¿øÇü¼¼Æ÷
  • sickle-cell anemia
    °â»ó(Àû)Ç÷±¸¼ººóÇ÷
  • signet-ring cell
    ¹ÝÁö¼¼Æ÷, ÀÎȯ¼¼Æ÷
  • small cell
    ¼Ò¼¼Æ÷
  • small cleaved cell
    ¼ÒºÐÇÒ¼¼Æ÷
  • spindle cell
    ¹æÃ߻󼼯÷
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • stem cell
    °£¼¼Æ÷
  • stromal cell
    °£Áú¼¼Æ÷
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • tumor cell
    Á¾¾ç¼¼Æ÷
  • white blood cell
    ¹éÇ÷±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
HDL-c high-density lipoprotein-cell surface
ICSA islet cell surface antibody
MCSA Moloney cell surface antigen
ST esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor...
TSSA tumor-specific cell surface antigen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MSP major surface protein
MSP-1 merozite surface protein-1
MSA1 Merozoite surface antigen 1
MSA2 Merzoite Surface Antigen 2
MSP-1(19) Merozoite surface protein 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • fatty coating of surface
    Ç¥¸éÀÌ Áö¹æÀ¸·Î µ¤Çô ÀÖ´Â
  • flexor surface
    ±¼°î¸é, ±¼±Ù¸é
  • free surface
    ÀÚÀ¯ ¸é
  • high surface
    °íÇ¥¸é
  • impression of root surface
    ±Ù¸é Àλó
  • impression surface
    Àλó¸é
    ±¸°­ Á¶Á÷ÀÇ ÀÎ»ó¿¡ ÀÇÇØ¼­ °áÁ¤µÈ ÀÇÄ¡ÀÇ Ç¥¸é.
  • inferior surface
    ¾Æ·¡ ¸é
  • inferior surface of tongue
    Çô ¾Æ·¡ ¸é
  • interfacial surface tension
    ÀÇÄ¡ Ç¥¸é Àå·Â
    ÀÇÄ¡ÀÇ Á¢ÇÕµµ°¡ ÁÁÀº °æ¿ì¿¡ À־ ÀÇÄ¡»ó°ú Á¶Á÷°úÀÇ »çÀÌ¿¡ ¾×ü°¡ ¾ãÀº ¸·À¸·Î Çü¼ºµÇ¾î ÀÇÄ¡ÀÇ Å»¶ôÀ» ¹æÁöÇÑ ÀúÇ×·ÂÀÌ´Ù.
  • jugular surface
    °æÁ¤¸Æ Ç¥¸é
  • keratotic surface
    °¢Áú Ç¥¸é
  • labial surface
    ¼ø¸é, ÀüÁ¤¸é
    1. ÀÔ¼ú ÂÊÀ¸·Î ÇâÇÑ ¸é. 2. Ä¡¾ÆÀÇ ÀÔ¼úÃø ¸é.
  • large surface form
    ³ÐÀº ¸éÀÇ ÇüÅÂ
  • laser cavity surface
    ·¹ÀÌÀú Çü¼º ¿Íµ¿¸é
    ·¹ÀÌÀú¸¦ »ç¿ëÇØ Ä¡¾Æ ¿ì½ÄºÎ¸¦ Á¦°ÅÇÏ°í ¿Íµ¿À» Çü¼ºÇÑ ¸é.
  • malleolar articular surface
    ³»°ú °üÀý¸é, ³»Ãø º¹»ç °üÀý¸é
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
S-receptor kinase <enzyme> Srk - s-receptor kinase; from brassica oleracea; amino acid sequence has been determined
Registry number: EC 2.7.1.-
Synonym: srk gene product
(26 Jun 1999)
steroid receptor Family of nuclear transcription factors, most of which are receptors for hormones of the steroid family, for example androgen, oestrogen, glucocorticoid, mineralocorticoid, progesterone, retinoic acid, ecdysone, thyroid hormone and the Drosophila transcription factors knirps, ultraspiracle and seven up. This family contains a conserved domain (the steroid finger motif) containing two C4 type zinc fingers.
(18 Nov 1997)
nicotinic acetylcholine receptor Integral membrane protein of the postsynaptic membrane to which acetylcholine binds. The receptor contains an integral ion channel, as a result of binding of acetylcholine, ion channels in the subsynaptic membrane are opened. at the neuromuscular junction, the nicotinic acetylcholine receptor initiates muscle contraction. Currently the best characterised ion channel protein: made of a hetero pentamer of related subunits, although a homo pentamer is functional in insects. Structural studies show that the acetylcholine binding site and the ionic channel are part of the same macromolecular unit. The nAChR mediates rapid transduction events (1ms) whereas receptors activating G-protein coupled channels operate on slower time scales (millisecond to second range).
(18 Nov 1997)
nicotinic cholinergic receptor A class of receptors responsive to acetylcholine that also are activated by nicotine; ganglionic (including the adrenal medulla) and neuromuscular receptors. Two classes exist: nicotinic-neuronal and nicotinic-muscular.
(05 Mar 2000)
NMDA receptor A type of glutamate receptor that participates in excitatory neurotransmission and also binds N-methyl-d-aspartate; may be particularly involved in the cell damage observed in individuals with Huntington's disease.
(05 Mar 2000)
N methyl D aspartate receptor <physiology> Glutamate receptor sub type (see excitatory amino acids). N methyl D aspartate receptor channels seem to be potentiated by intracellular arachidonic acid.
Acronym: NMDA
(26 Mar 1998)
quisqualate receptor <cell biology> Glutamate operated ion channel.
See: excitatory amino acid receptor channels.
(05 Feb 1998)
insulin receptor Areas on the outer part of a cell that allow the cell to join or bind with insulin that is in the blood. When the cell and insulin bind together, the cell can take glucose (sugar) from the blood and use it for energy.
(09 Oct 1997)
insulin receptor protein-tyrosine kinase <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of the insulin receptor.
Registry number: EC 2.7.1.-
(12 Dec 1998)
insulin receptor substrate-1 protein <chemical> Amino acid sequence given in first source; a 180 kD protein that contains multiple phosphorylated tyrosine residues after insulin stimulation; human and rat forms (hirs-1 and irs-1) are homologous
Synonym: insulin receptor substrate-1-like protein, irs-1 protein, irs-1 gene product, hirs-1 protein, hirs-1 gene product, insulin receptor substrate 1, insulin receptor substrate-1
(05 Dec 1998)
oestrogen receptor <cell biology> Cytoplasmic proteins that bind oestrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of oestrogen receptors in breast cancer patients has become clinically important and determines the likelihood of response to anti-oestrogen therapy with tamoxifen.
(17 Jul 2002)
olfactory receptor cells Very slender nerve cell's, with large nuclei and surmounted by six to eight long, sensitive cilia in the olfactory epithelium at the roof of the nose; they are the receptors for smell.
Synonym: olfactory cells, Schultze's cells.
(05 Mar 2000)
olfactory receptor neurons Neurons in the olfactory epithelium with proteins (receptors, odourant) that bind, and thus detect, odourants. Olfactory receptor neurons are bipolar. They send to the surface of the epithelium apical dendrites with non-motile cilia from which project odourant receptor molecules. Their unmyelinated axons synapse in the olfactory bulb of the brain. Unlike other neurons, they can be generated from precursor cells in adults.
(12 Dec 1998)
opiate receptor <pharmacology> Opiate-binding sites found throughout primary afferents and the neuraxis.
(16 Dec 1997)
opioid receptor <pharmacology> A membrane protein, widely distributed in animal cells, but especially in the brain (enkephalin receptors) and gut. The natural ligands are the opiate peptide neurotransmitters, but the name is given because opiates are potent agonists that occupy the receptors and mimic the action of the natural transmitters.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • wet cell
    ½ÀÀüÁö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á